A new drug for adhesion dermatitis (AD) ! AbbVie oral JAK inhibitor Rinvoq single drug treatment medium-heavy AD phase III study was successful!

, June 19, 2020 /
BiovalleyBIOON/AbbVie recently announced the top-line results of the oral JAK1 inhibitor Rinvoq (upadacitinib) single drug treatment of adhesyn dermatitis (AD) Phase III clinical study (Measure Up 1)The study was conducted in moderate to severe AD adolescents and adult patients, and data showed that rinvoq (15mg and 30mg, once a day) reached the common primary endpoint in the 16th week of treatment: the eczema area and severity index improved by at least 75% (EASI75), and the validated general researcher assessment of adhectal dermatitis (IGA-AD) scored a total or almost complete removal of skin damage (0/1)In addition, two doses of Rinvoq also effectively and rapidly reduced itching, compared to placebo, 30 mg dose stake on the day after the first administration (day 2), 15 mg dose two days after the first administration (day 3) showed a clinically significant improvement in itchingMeasure Up 1 is the first critical Phase III study to evaluate moderate-to-severe atopic dermatitis (AD) in Rinvoq treatmentIn this study, patients treated with 15 mg or 30 mg of upadacitinib single drug showed significant improvement in skin loss removalThe specific data were: (1) in the 16th week of treatment, 70% of patients in the Rinvoq 15mg group and 80% of patients in the 30mg group reached EASI 75, and the placebo group was 16% (p 0.001)(2) In the 16th week of treatment, 48% of patients in the Rinvoq 15mg and 30mg groups achieved a vIGA-AD score of 0/1, while the placebo group had a score of 0/1 (p 0.001), patients at both doses experienced early itching relief until the first 16 weeksClinically itching relief is defined as the most severe itching numerical lyse scale (NRS) improved by .4The data showed that in the 16th week of treatment, the proportion of patients in the 15 mg group and the 30 mg group who achieved clinically significant increasein itching improvement compared to the placebo group (52%, 60%, 12, p 0.001, respectively)Of particular concern is the clinically significant reduction in itching observed in the 30mg group on the day (day 2) after the first administration and two days after the first administration (day 3) compared to the placebo group (30mg group vs placebo group , 12% vs 4%, p 0.001; 155 The vsplacebo group vs 16% vs 3%, p 0.001no new safety risk was observed in Rinvoq treatment in patients withrheumatoid arthritis(RA) and psyllitus arthritis (PSA) compared to those treated with Rinvoqthe full results of the study will be published at a future of the Medical Conference and will be published in the peer-reviewed journal -specific dermatitis (AD) is a common, chronic, recurrent, inflammatory skin disease, manifested as repeated circulation of itching and scratching, resulting in skin pain and rupture It is estimated that up to 25 percent of adolescents and 10 percent of adults will be affected by AD at some point in their lives 20%-46% of adult AD patients have moderate to severe illness The symptoms of the disease can place a significant physical, psychological and economic burden on the patient Dr Michael Severino, Vice President and President of AbbVie, said: "Patients with teriolyderitis often struggle with relentless skin and itching symptoms, leading to severely unmet medical needs We are excited about these results, which show the therapeutic potential of Rinvoq for patients with teriototitis "Adolescents and adults with moderate to severe optoderitis often bear a huge burden of disease that affects every aspect of their daily lives," said Emma Guttman Yassky, M.D., of Dermatology and Immunology at the Icahn School of Medicine at Mount Sinai Medical Center in It is encouraging to note that a high percentage of patients treated with upadacitinib received complete or almost complete removal of skin damage, and that both doses of the drug were effective and rapid in reducing itching "
Rinvoq's active drug ingredient is upadacitinib, an oral selective and reversible JAK1 inhibitor found and developed by AbbVie, which is being developed to treat several immuno-mediated inflammatory diseases JAK1 is a kinase that plays a key role in the pathophysiological process esccophysiology of a variety of inflammatory diseases August 2019, Rinvoq was the world's first to treat adult patients with moderate to severe active arthriti
s (RA) who have inadequate or intolerable responsetos to methotrexate (MTX) In December 2019, Rinvoq was approved by the European Union for the treatment of adult patients with moderate to severe RA who do not respond to or tolerate an inadequate response to one or more disease-modified anti-rheumatic drugs (DMARD) In RA, the approved dose of Rinvoq is 15 mg currently, A Phase III clinical study of Rinvoq's treatment of psoriasis arthritis (PsA), RA, mid-axis spinal arthritis (axSpA), Crohn's disease (CD), teriotorthemy (AD), ulcerative colitis (UC), and cytomegaloartis (GCA) is under way just recently, AbbVie announced that it had submitted a new indication application for Rinvoq (upadacitinib, 15mg, daily) in the United States and the European Union for the treatment of active PsA adult patients the industry is very bullish on Rinvoq's business prospects In a previous report, Evaluate Pharma, a pharmaceutical market research firm, predicted that Rinvoq's global sales would reach $2.57 billion in 2024, making it the world's fifth-best-selling anti-rheumatic drug (BioValleyBioon.com) original source: RINVOQ? (upadacitinib) Monotherapy Shows Change in Skin Clearance and Itch in First Phase 3 Study for Atopic Dermatitis .